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The prevalence of Alzheimer’s disease (AD) has increased with the fast growing of
aging population, thereby posing great challenges to provision of care for AD patients.
Pharmacists play a vital role in the management of AD; this includes recognizing early
symptoms of AD, providing medication counseling to AD patients and their caretakers,
and identifying potential adverse drug reactions. A comprehensive understanding of the
disease progression, as well as the pharmacological therapy, is essential to provide
effective care to AD patients. The level of knowledge about AD among the pharmacists,
however, remains unknown. Hence, this study aimed to assess the knowledge on
AD among the pharmacists in public hospitals and health clinics and its correlates. A
clear picture of the characteristics associated with different levels of knowledge could
facilitate the targeted re-training of pharmacists. The 30-item validated Alzheimer disease
knowledge scale (ADKS) tool was pilot-tested and used in this cross-sectional study.
All pharmacists, from nine public hospitals and seven public health clinics in the State
of Selangor, Malaysia, were invited to participate in this cross-sectional survey. The
ADKS score was computed and compared across demographics characteristics. A
total of 445 pharmacists responded to the survey. These pharmacists had a moderate
overall score in ADKS; nevertheless, high scores were recorded in the domains of
treatment management and care giving. No difference in AD knowledge was found
among pharmacists worked in public hospitals and health clinics, except for the domain
of care giving (p = 0.033). Ethnicity and age group were independent predictors of
ADKS score in the current study. The pharmacists in the current study had moderate
AD knowledge. On-going education and training programme on AD, in particular the
domains other than treatment management and care giving, should be provided to the
pharmacists to ensure delivery of quality care to AD patients.
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INTRODUCTION
More than 46 million people worldwide are living with
Alzheimer’s disease (AD) and the number is expected to increase
to 131.5 million by 2050, with the majority are from low and
middle income countries (Alzheimer’s Disease International,
2015). The estimated cost of managing AD was at US$818
billion and it is forecasted to increase to a trillion dollar by
2018 (Alzheimer’s Disease International, 2015). The prevalence of
dementia in Malaysia is estimated at 0.126% and 0.454% in 2020
and 2050, respectively (Rees et al., 2006; Tey et al., 2016). This is
due to the fact that most family members view AD’s symptoms as
normal aging, and hence, do not seek for any medical treatments
(Alzheimer’s Disease International, 2015).
Management of AD patients is complex as the development
of psychiatric and behavioral disturbances upon pharmacological
treatment might overlap with the symptoms of cognitive decline
(Feinberg and Michocki, 1998). Pharmacists are a valuable
member of the healthcare team in managing patients with AD.
They are trained to identify potential adverse drug reactions
(ADR), helping the clinicians to rule out the possibility of these
ADRs that may appear to be AD symptoms (Marasco et al.,
2003). In addition, pharmacists can monitor for the safety and
efficacy of medications and medication adherence among the
AD patients (Chang et al., 2015). Pharmacists can educate AD
patients and their caregivers, ensuring that they keep abreast with
new drug therapies and updated resources (Chang et al., 2015).
More recently, the role of pharmacists in the early detection of
AD is increasingly emphasized as they are highly visible and
easily accessed by the community (Criddle, 2014).
Inadequate knowledge in regards to AD among the healthcare
professionals have been shown to be negatively impacted patient
outcomes (Barrett et al., 1997; Perry et al., 2008). Studies have
revealed that some primary care physicians failed to properly
evaluate and manage patients with AD due to inadequate
training (Barrett et al., 1997). A recent survey conducted among
community pharmacists in Maltese Islands revealed that the
respondents generally had inadequate knowledge on risk factors,
caregiving issues, and pharmacotherapy of AD (Zerafa and
Scerri, 2016). These indicate a need for continuous knowledge
empowerment on AD among the healthcare professionals in
order to provide better care to AD patients (Rubio-Valera
et al., 2014). Limited studies have been conducted to assess the
knowledge on AD among the healthcare professionals (Barrett
et al., 1997; Smyth et al., 2013), in particular the pharmacists in
the public healthcare institutions whom are regularly accessed
by the public. Accordingly, this study aimed to (i) assess the
AD knowledge among the pharmacists working in the public
hospitals and health clinics in the state of Selangor, Malaysia,
and (ii) correlate the demographics that affect pharmacists’
knowledge on AD.
MATERIALS AND METHODS
Participants and Settings
This cross-sectional study was conducted between September
and November 2016. All pharmacists who worked in public
hospitals and health clinics in Selangor, Malaysia, were invited
to participate in this study. The list of the pharmacists with
their email addresses was obtained from Selangor State Health
Department.
Questionnaire and Data Collection
A 38-item survey, which included questions on: (i) demographics
of the pharmacists, (ii) validated items from Alzheimer’s disease
Knowledge Scale (ADKS) (Carpenter et al., 2009), and (iii)
self-rated AD knowledge level, was used in this study. This
instrument was selected to measure the knowledge of AD due
to its ease of use, demonstrated reliability and validity, and also
its suitability to be applied for diverse pools of respondents
including general public, caregivers, and healthcare professionals
(Smyth et al., 2013). The ADKS consisted of 30 true/false items,
which further divided into seven content domains (i.e., risk
factors, assessment and diagnosis, symptoms, course, life impact,
caregiving, and treatment and management). The total ADKS
score was calculated by adding the correct responses to produce
a score that ranges from 0 to 30. Moreover, the respondents were
asked to self-rate their level of knowledge on AD based on a scale
from 0= I know nothing at all to 10= I am very knowledgeable.
This survey took about 10–15min to complete. A pilot study
was conducted among 33 pharmacists (which were not included
into the data analysis) to determine face and content validity as
well as reliability of ADKS. The Cronbach’s alpha value was 0.6,
indicating an internal consistency of ADKS among this cohort
(Bhatnagar et al., 2014).
The survey was distributed via two approaches: (i) using
a web-based questionnaire, hosted by www.surveymonkey.com
(for those pharmacists who worked in hospitals and health
clinics at 15 km or more from the city center) and (ii)
manual distribution of hard copy of the survey (for those
pharmacists who worked in nearby hospitals and health clinics).
For web-based survey, an invitation email containing a detailed
explanatory statement for participation and a link to the survey
were sent to all pharmacists. The first reminder was sent 2 weeks
after the initial invitation email and a total of three reminders
were sent within the survey period. For the manually distributed
survey, the surveys were collected 2 weeks after the distribution.
Ethical Approval
Ethics approvals from Research Ethics Committee (REC) of
Universiti Teknologi MARA (UiTM) [Reference no: 600-
IRMI (5/1/6) REC/345/16] and Medical Research and Ethics
Committee (MREC) [Reference no: NMRR-15-133-24229(IIR)],
Ministry of Health, Malaysia, were obtained for the purpose of
this study.
Statistical Analyses
Descriptive data were analyzed by using Statistical Package for
Social Science (SPSS) programme version 20.0 and Microsoft
Excel version 2010. Descriptive statistical analysis, such as
frequency, percentage, mean, and standard deviation (SD) was
carried out to analyze demographic data. Descriptive statistics for
all independent variables were calculated and the mean ADKS
scores across different groups were compared using independent
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t-tests and ANOVA test. The predictor of ADKS score was
determined using multiple linear regression.
RESULTS
Demographics Characteristics
Of the total 775 pharmacists, 445 responded to the survey, giving
a response rate of 57.4%. There was almost an equal participation
of pharmacists from the public hospital and health clinics
(Table 1). The demographics of the respondents are shown in
Table 1. The respondents were mainly female (83.4%). Half of the
respondents were Malay (53.5%), followed by Chinese (35.5%),
Indian (10.3%), and other ethnicities (0.7%). The mean age of
the respondents was 28.94 ± 3.37 years old. The majority of the
respondents had Bachelor degree (92.8%) and the reminders were
Master holders. Most of them have working experience of 4–
7 years (42.2%) and only 2.2% of the respondents have worked
for 12–14 years. The respondents were mainly from outpatient
pharmacy (57.1%), followed by inpatients pharmacy (12.1%).
Only 1.6% was from the parenteral nutrition unit.
Relationships between AD Knowledge and
Demographic Characteristics
The mean (SD) total ADKS score for health clinics pharmacists
was 19.05 (3.69), with 63.5% correct answers, whereas hospital
pharmacists’ score was 18.47 (3.56), with 62.5% correctness
(Table 1). Both scores were categorized as intermediate score
with no significant difference detected between the pharmacists
from public hospitals and health clinics (p = 0.095). Significant
differences in total ADKS score were noted for different age
group (p = 0.009), ethnicity (p = 0.039), and pharmacy unit
(p = 0.016) of the respondents (Table 1). Interestingly, ADKS
score for this cohort was independent of the education level
[i.e., Master vs. Bachelor (p = 0.655)]. As for self-rated AD
knowledge, the respondents rated themselves as having average
AD knowledge, with a mean (SD) of 4.22 (1.77), based on a
11-point scale. There was a significant correlation between self-
rated knowledge and ADKS score, whereby the respondents who
rated low knowledge tended to have lower ADKS score (r = 0.33,
p= 0.001).
Difference in ADKS Domains Scores
between Public Hospitals and Health
Clinics Pharmacists
As shown in Table 2, pharmacists from both public hospitals
and health clinics had lower percentage of correctness in
two of the domains, namely symptoms (46.2%) and course
of disease (48.3%). On the other hand, all pharmacists had
higher percentage of correctness in the domain of treatment
management and care giving, with a score of 76.4 and 72.1%,
respectively. For the domain of life impact (52.7%) and risk
factors (59.8%), all pharmacists in this study had average
percentage of correctness. There was no significant difference in
the mean scores between the public hospital and health clinics
pharmacists in any of the domain except the domain of care
TABLE 1 | Demographic characteristics and their relationship to AD knowledge
(n = 445).
Demographic
characteristics
n (%) Mean ADKS
score (SD)
F df P-value
GENDER
Male 74 (16.6) 19.23 (4.17) 1.054 443 0.225a
Female 371 (83.4) 18.67 (3.52)
EDUCATION LEVEL
Bachelor degree 414 (92.8) 18.83 (3.66) 0.2 443 0.655a
Master degree 31 (7.0) 17.90 (3.36)
PREMISES
Health clinic 225 (50.6) 19.05 (3.69) 0.142 443 0.095a
Hospital 220 (49.4) 18.47 (3.56)
AGE GROUP
<30 335 (75.3) 19.03 (3.69) 3.43 2,442 0.009b,c
31–40 106 (23.8) 17.99 (3.44)
41–50 4 (0.9) 18.06 (1.03)
ETHNICITY
Malay 238 (53.5) 19.21 (3.86) 2.82 3,441 0.039b,c
Chinese 158 (35.5) 18.13 (3.24)
Indian 46 (10.3) 18.72 (3.64)
Others 3 (0.7) 18.33 (0.58)
WORKING EXPERIENCE
<3 174 (39.1) 18.73 (3.68) 0.172 4,440 0.953b
4–7 188 (42.2) 18.80 (3.61)
8–11 70 (15.7) 18.65 (3.58)
12–14 10 (2.2) 19.00 (6.16)
>15 3 (0.7) 18.76 (3.64)
PHARMACY UNIT
Outpatient pharmacy 254 (57.1) 19.21 (3.76) 2.299 9,435 0.016b,c
Store 47 (10.6) 17.55 (2.67)
Clinical pharmacy 54 (12.1) 17.81 (3.11)
Drug information services 23 (5.2) 17.91 (3.78)
Total parenteral nutrition 7 (1.6) 21.14 (4.05)
Others 60 (13.4) 17.16 (3.05)
a Independent t-test.
bOne-way ANOVA test (post-hoc test LSD procedure).
cP-value is significant (<0.05).
giving where the public hospital pharmacists scored significantly
higher than the health clinics pharmacists (p= 0.033).
Predictors of ADKS Score
Findings from multiple linear regression analysis (Table 3)
revealed that aged <30 and Malay ethnicity as independent
predictors of ADKS score. Malay ethnicity had 0.9 point higher
ADKS score compared to Chinese (adjusted B = 0.89, 95% CI
= 0.219, 1.557, p = 0.009). Those respondents aged <30 had 0.8
point higher ADKS score compared those aged between 31 and
40 (adjusted B= 0.83, 95% CI = 0.059, 1.600, p= 0.018).
DISCUSSION
The role of pharmacists in management of AD is increasingly
recognized, which includes recognizing early symptoms of
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TABLE 2 | ADKS content domain scores between public hospitals and health clinics pharmacists.
Domain No of Item Mean (SD) ADKS score
for both groups
% correct Mean (SD) ADKS score P-valuea
Hospital pharmacists
(n = 220)
Health clinics
pharmacists (n = 225)
Life impact 3 1.58 (0.77) 52.7 1.58 (0.53) 1.57 (0.05) 0.898
Risk factors 6 3.59 (1.22) 59.8 3.64 (0.08) 3.53 (0.82) 0.356
Symptoms 4 1.84 (1.05) 46.2 1.92 (0.07) 1.77 (0.07) 0.131
Treatment management 4 3.05 (0.81) 76.4 3.06 (0.05) 3.04 (0.05) 0.829
Assessment 4 2.67 (0.91) 66.8 2.67 (0.06) 2.66 (0.58) 0.932
Care giving 5 3.60 (1.07) 72.1 3.71 (0.06) 3.49 (0.07) 0.033b
Course of disease 4 2.41 (1.00) 48.3 2.44 (0.66) 2.38 (0.068) 0.437
a Independent t-test.
bP value is significant (<0.05).
TABLE 3 | Regression model predicting knowledge of AD among pharmacists.
Variables Single linear regression Multiple linear regression
Ba (95% CI) P-value Bb (95% CI) P-value
PREMISES
Health clinic – – – –
Hospital −0.54(−1.220, 0.135) 0.116
GENDER
Male – –
Female −0.56(1.473, 0.347) 0.225
EDUCATION LEVEL
Bachelor degree – –
Master degree −0.93(−2.261, 0.401) 0.170
AGE GROUP
<30 1.035 (0.285, 1.811) 0.009c 0.83 (0.059, 1.600) 0.018c
31−40 –
41−50 0.75 (−2.87, 4.371) 0.684
ETHNICITY
Chinese – –
Malay 1.078 (0.348, 1.809) 0.004c 0.89 (0.219, 0.557) 0.009c
India 0.598 (−0.602, 1.78) 0.331
Others 0.206 (−3.939, 4.351) 0.922
aCrude regression coefficient.
bAdjusted regression coefficient.
cP-value is significant (<0.05).
Forward multiple linear regression method applied. Model assumption are fulfilled.
There was no interaction amongst independent variable. No multicollinearity detected.
Coefficient of determination (R2 ) = 0.044.
AD, referring AD patients to seek for timely diagnosis
and treatment, identifying potential ADRs of pharmacological
treatment, and educating and providing counseling to the
AD patients and caregivers. For example, findings from a
study on multi-disciplinary dementia care services conducted
in Germany revealed that pharmacists are adapt in identifying
problems related to drug administration, adherence, and drug
interaction among patients with dementia (Wucherer et al.,
2017). Meanwhile, in the United Kingdom, a trial targeting
people with dementia initiated on anti-psychotics demonstrated
that pharmacist-led medication review successfully limited the
prescribing of anti-psychotics to people with dementia because
of the increased risk of ADRs (Child et al., 2012). In Japan,
study involving hospital pharmacists on donepezil consultation
for patients with AD and their caregivers has demonstrated
an enhanced medication adherence though this drug could
cause insomnia and gastrointestinal disturbance (Watanabe et al.,
2012). In Malaysia, while medication reviews for patients with
other chronic diseases have been implemented by hospital
pharmacists via medication therapy adherence clinics (Lim et al.,
2016; Aidit et al., 2017), this has not been done for AD patients.
It is important to ensure that the pharmacists are equipped
with proficient knowledge on AD because poor management in
AD can result in side effects, inappropriate dosing, and non-
compliance to medications (Stafford, 2015).
This study, the first in Asia region, assessed the level of
AD knowledge among the pharmacists in public hospitals and
health clinics by using ADKS. This study revealed that the
pharmacists from both public hospitals and health clinics in
the state of Selangor had moderate knowledge on AD. It is
unknown whether the current scores are on par with the
regional and international counterparts as no similar study
was conducted except one involving community pharmacists at
Maltese Islands (Zerafa and Scerri, 2016). The score attained
by the Malaysian pharmacists, though better than the Maltese,
was lower than the scores obtained by psychologists and
medical professionals reported in other study, with mean ADKS
scores of 24.10 and 26.08, respectively (Smyth et al., 2013).
The critical role and active participation of psychologists and
medical professionals throughout the lifespan of the AD illness
encompasses prevention, diagnosis, and treatment may attribute
to their better knowledge on AD (American Psychological
Association, 2014). It also appears that the pharmacists’ working
setting (i.e., hospital vs. health clinic) did not affect their total
ADKS score.
It is interesting to note that pharmacists with a master
education did not score better than the bachelor holders. It is
unfortunately that the survey did not elicit the specialty of the
Frontiers in Pharmacology | www.frontiersin.org 4 October 2017 | Volume 8 | Article 739
Mat Nuri et al. Pharmacists’ Knowledge on Alzheimer’s Disease
master holders, and therefore, it is unclear whether AD was
part of the learning focus during the master training. Of note,
there was no difference in the mean ADKS score between the
hospital pharmacists and health clinics pharmacists except in
one domain (i.e., care giving). The score for the care giving
domain was higher among the pharmacists in public hospitals
compared to those worked in the health clinics. This could be
due to the fact that hospital pharmacists have more encounters
with AD patients or caregivers in the geriatric clinics or wards.
The pharmacists scored lowest in domains such as symptom
and course of disease. Indeed, these two domains have more
medically-oriented questions, which may not be the primary
focus of their job scopes, for example, the stages of cognitive
impairment in people with AD and the lifespan of people with
AD generally can survive.
There was a positive correlation between ADKS score and
self-rated AD knowledge using a 11-point scale (r = 0.33,
p < 0.001), consistent with the previous study which compared
the AD knowledge among the healthcare providers (i.e., nursing,
medical, allied health, and support) (Smyth et al., 2013). The
respondents who rated themselves having low knowledge tend to
score lower on ADKS. This shows a good self-awareness among
the pharmacists on their inadequate knowledge on AD and may
serve as a motivation for them to acquire latest information on
AD, particularly, if they are to be provided with the opportunity
via continuous professional development (CPD) or refresher
courses.
In the current study, the age group (i.e., age <30) was found
to be a significant independent predictor of higher ADKS score.
This is consistent with an Australian study that surveyed the
nursing, medical, support, and allied health staff, which revealed
that age bracket of <30 years old scored 1.0 point ADKS higher
than other age groups (Smyth et al., 2013). This could be due to
the updated pharmacotherapy syllabus related to dementia and
AD taught during the undergraduate pharmacy. Interestingly,
unlike this study, age and duration of working did not correlate
well with increased knowledge (Zerafa and Scerri, 2016). In fact,
this highlights the need of CPD or refresher courses on AD
to equip all pharmacists, regardless of seniority, with the latest
information on AD. Targeted information on the symptoms and
course of disease of AD may be, in particularly, relevant as the
pharmacists scored poorly on these areas.
Malay pharmacists had a significantly higher ADKS score and
were an independent predictor associated with higher ADKS
score in the current study. This interesting finding could be
related to their exposure and personal experience in handling AD
among their family members due to the greater prevalence of AD
among in Malay ethnicity (Kua and Ko, 1995; Kadir et al., 1997;
Tey et al., 2016). Unlike developed countries where residential
care is provided to older people especially those with AD, certain
Asian countries, such as Malaysia, still rely on family members
on their daily living (Scerri, 2016). This indirectly creates a
higher awareness on AD and stimulates the interest among the
Malay pharmacists to enhance their understanding on AD. The
variance in the current study was lower (4.4%) than the study
by Smyth et al. (i.e., 14.0%) (Smyth et al., 2013). This could
be due to the fact that only one population (i.e., pharmacists),
instead of diverse groups or different healthcare settings, was
surveyed.
There are several limitations in this study. Some respondents
may have referred to any resources while answering this
questionnaire. In addition, the current study did not evaluate the
previous training and personal experience on AD (e.g., family
member with AD), which could have an impact on the ADKS
score. Furthermore, this study was conducted at only one region
in Malaysia (i.e., Selangor), and thus, the findings from this study
cannot be generalized to all pharmacists in Malaysia.
CONCLUSION
In the present study, the majority of the pharmacists have
moderate ADKS score. No difference in AD knowledge was noted
among the pharmacists working in public hospitals and health
clinics except in the care giving domain. AD-specific education
training would have benefited these pharmacists in providing
better care to AD patients.
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